Articles tagged with Small Cell Lung Cancer
A prospective study found that MRI outperformed conventional tests and FDG PET/CT for various staging endpoints in SCLC. Whole-body MRI and FDG PET/MRI were more accurate than FDG PET/CT for assessing local invasion extent.
A study analyzed open and closed insurance claims to assess practice behavior changes after durvalumab approval. The results showed a low rate of durvalumab utilization, with higher rates in patients over 65 and treated in the Midwest.
Recent studies published in the Journal of Thoracic Oncology have found that rovalpituzumab tesirine is not effective against small cell lung cancer, despite initial promise shown in early clinical trials. The therapy has been plagued by high rates of side effects and lack of survival benefits.
In the NRG-LU001 clinical trial, adding metformin to concurrent chemoradiation did not improve one-year progression-free survival (PFS) in patients with locally advanced non-small cell lung cancer. The study found nearly identical overall survival rates between the two groups.
Researchers at H. Lee Moffitt Cancer Center & Research Institute will investigate common metabolic pathways in lung cancer, with the goal of developing novel therapies. The four distinct projects aim to unveil common metabolic mechanisms regulated by genetic drivers across non-small cell lung cancer types.
A new study found that a non-pungent synthetic capsaicin analog, arvanil, made small cell lung cancer cells more responsive to chemotherapy. The compound enhanced the anti-cancer activity of SN38, a commonly used treatment for relapsed small cell lung cancer.
The study identified 42 deleterious variants in 35 genes among patients with small cell lung cancer, including MLH1, BRCA2, and MUTYH germline mutations. These variants were associated with increased risk of first-degree relatives with cancer or lung cancer and longer recurrence-free survival following platinum-based chemotherapy.
A new study reveals racial and socioeconomic disparities in treating patients with extensive-stage small cell lung cancer. Black patients are less likely to receive chemotherapy compared to white patients, despite improved survival rates. Insurance status and education level also impact treatment and survival outcomes.
The addition of sintilimab to pemetrexed and platinum chemotherapy significantly improved progression-free survival in patients with non-squamous non-small cell lung cancer, with a nearly two-fold increase observed. The overall response rate was also higher in the sintilimab-combination group compared to the placebo combination.
A single-center retrospective study of 282 patients with early or locally advanced lung adenocarcinoma found that EGFR-mutated lung cancer had increased rates of metastatic recurrence. Early identification of these recurrences is crucial, given the improved post-relapse survival observed in this population.
The largest ever study of radiosurgery for brain metastases from small cell lung cancer has been published in JAMA Oncology. The analysis found that patients treated with first-line stereotactic radiosurgery (SRS) had a median overall survival of 8.5 months, compared to 6.2 months for those treated with whole-brain radiation (WBRT). Ad...
Scientists have made a breakthrough discovery in understanding small cell lung cancer, finding that it can change and adapt to evade treatments. The study suggests that the tumor is like a 'moving target' that requires multiple treatments to be effective.
Researchers developed a novel method to analyze chemotherapy-resistant tumors using circulating tumor cells. Single-cell RNA sequencing revealed gene expression differences between individual cells, providing insight into the evolution of multiple resistance mechanisms.
Recent advances in immunotherapy are starting to show hope for small cell lung cancer patients, but current treatments have limited durability and many patients don't respond. Researchers call for further exploration of underlying disease mechanisms and development of predictive biomarkers to advance the field.
The CheckMate 451 study found that maintenance immunotherapy did not prolong overall survival in patients with extensive-stage small cell lung cancer. However, the study suggested that patients who received early maintenance therapy may have longer progression-free survival rates.
Researchers found a promising new treatment for small cell lung cancer by combining immune checkpoint blockade with targeted therapies that block DNA damage repair. This combination achieved significant tumor regression in mouse models, suggesting potential benefits for patients.
Researchers at UCLA have discovered that late-stage prostate and lung cancers share common molecular mechanisms. The study found that these cancers can evolve similarly, even from different organs, which could lead to the development of drugs to treat not just prostate and lung cancers but also small cell cancers of almost any organ.
A Phase II trial found that adding PARP inhibitor veliparib to standard chemotherapy improved overall response rates and progression-free survival in patients with small cell lung cancer. Researchers identified SLFN11 as a biomarker for patient selection, which may lead to new treatment options.
Vanderbilt University has received a five-year, $8.1-million grant from the National Cancer Institute to study small cell lung cancer, a highly aggressive and incurable tumor. The new center will use a multidisciplinary approach combining experimentation, mathematical modeling, and machine learning to develop new treatment avenues.
PharmaMar presents positive results of PM1183 (lurbinectedin) in a cohort of 36 patients with advanced and relapsed small-cell lung cancer (SCLC), achieving an objective response rate of 36%. This finding is significant given the limited therapeutic options for SCLC, which has a high mortality rate.
The IASLC published a comprehensive summary of the year's key developments in thoracic oncology, covering prevention, early detection, pathology, staging, surgery, adjuvant therapy, radiotherapy, and immunotherapy. The publication highlights significant progress in small cell lung cancer and malignant mesothelioma.
Scientists at Huntsman Cancer Institute discovered distinct types of tumors within small cell lung cancer that respond differently to treatment. A targeted drug combination showed improved outcomes for one specific tumor type, suggesting a need for genetic testing and personalized therapies.
Scientists identified a target that could lead to the development of new drugs targeting small cell lung cancer while sparing healthy cells. The research found that amplifying a gene's effect spurred tumor growth in mice, but blocking it suppressed tumor growth.
PharmaMar starts a pivotal Phase III ATLANTIS study evaluating efficacy and safety of PM1183 in combination with doxorubicin versus topotecan or VCR for patients with SCLC after prior platinum-containing line failure. The primary endpoint is to improve progression-free survival.
Researchers identified ASCL1 as an essential protein in the development of small cell lung cancer, and deleting it in mice prevented cancer formation. The study highlights a new potential target for treatment, offering hope for improving survival rates for patients with this devastating disease.
A study by Stanford University researchers has identified CD47, a protein highly expressed on the surface of small-cell lung cancer cells, as a potential therapeutic target. Blocking this protein with immunotherapies may stimulate the immune system to destroy cancer cells, offering new hope for treating this deadly disease.
Researchers at Marshall University have found that blocking small cell lung cancer tumors' blood supply can delay their growth and regrowth after treatment. Synthetic molecules like MG624 show promise in delaying cancer relapse and improving patient outcomes.
A phase I trial of rovalpituzumab tesirine has shown promising results in treating small cell lung cancer, with 34% of patients experiencing a partial response and 31% experiencing disease stabilisation. The drug targets DLL3, a protein highly expressed in SCLCs.
The combination treatment induced objective responses in 67% of patients with small cell lung cancer, including 10% complete responses. Durable responses were observed, with an overall progression-free survival of 4.6 months.
University Hospitals Case Medical Center researchers will present data from several new studies evaluating a potential novel combination treatment for cancer patients with advanced solid tumors. Additionally, experts will analyze gene mutations in small cell lung cancer, revealing significant clinical correlation to overall survival an...
PharmaMar presents clinical studies showcasing the efficacy of YONDELIS and PM1183 in treating small cell lung cancer, soft tissue sarcoma, and malignant pleural mesothelioma. The studies demonstrate promising results with a response rate of 67% for PM1183 in SCLC.
Research reveals FGFR1 amplification in 22.7% of small cell lung cancer tumors, implying applicability to non-small cell lung cancer treatments
Cancer Research UK scientists found that mutations in the KRAS gene interfere with protective self-destruct switches, allowing cancer cells to grow and spread. The research may lead to tailored treatments for pancreatic and non-small cell lung cancers.
Analysis of over 600 small cell lung cancer and neuroendocrine tumors identified common molecular markers, including EGFR amplification, that could reveal new therapeutic targets. The study found notable differences in biomarker expression between SCLC and NET tumors.
Two recent studies by University Hospitals Seidman Cancer Center have identified potential new treatments for small cell lung cancer, including a link between the RET mutation and sensitivity to targeted therapies.
Researchers at VCU Massey Cancer Center have identified a critical protein called Noxa, which helps regulate the function of MCL-1 and makes cancer cells more sensitive to ABT-737. This breakthrough may lead to improved therapies for small cell lung cancer, overcoming resistance to conventional chemotherapies.
Researchers identified key mutations and genetic disturbances that arise at certain stages of lung cancer development, including a gene called Mycl1 that is found in nearly all tumor cells. They also discovered that loss of the Pten gene leads to overactive cell growth and rapid tumor progression.
The study identifies MAX as a tumor suppressor gene in aggressive lung cancer, which regulates the expression of BRG1 through direct recruitment to the MAX promoter. The depletion of BRG1 hinders cell growth and is synthetic lethal with MAX-deficient tumors.
A study published in Cancer Discovery reveals PARP1 and EZH2 as potential therapeutic targets for small cell lung cancer. The discovery could lead to the development of targeted treatments for this aggressive type of cancer, which currently has limited treatment options.
A genome-wide scan of small cell lung cancers reveals an association between SOX2 gene amplification and aggressive disease. Overproduction of SOX2 proteins may ignite or sustain abnormal cell growth in the lung.
Cancer biologists have pinpointed a gene that drives progression of small cell lung cancer, an aggressive form of lung cancer. Researchers found the gene to be overexpressed in both mouse and human lung tumors.
Researchers identified three microRNAs linked to chemoresistance in small cell lung cancer, affecting up to 15-30% of patients who are resistant to first-line therapy. The study provides new insights into predicting patient response to treatment and designing targeted therapies.
A Phase II study conducted by the University of Texas M. D. Anderson Cancer Center has shown encouraging results in treating limited stage small cell lung cancer with a combination of accelerated high-dose radiotherapy and chemotherapy, achieving a high level of control of the disease while minimizing damage to the esophagus.
Researchers found no evidence of improved survival with thalidomide treatment for small cell lung cancer. However, patients treated with thalidomide had a higher risk of thrombotic events.
A randomized controlled trial found that high-dose chemotherapy did not increase survival rates for patients with small cell lung cancer. Despite increased tumor shrinkage, the high-intensity approach was deemed ineffective and highly toxic.
Lilly Oncology will present data on three oncology agents, ALIMTA, GEMZAR, and enzastaurin, at the 43rd Annual Meeting of the American Society of Clinical Oncology. The company's studies focus on various types of cancer, including non-small cell lung cancer and breast cancer.
A clinical trial found that elderly patients with locally advanced limited stage small cell lung cancer can benefit from combined modality therapy, with similar two- and five-year survival rates compared to younger patients. However, severe pneumonitis was more common in the elderly group.
Researchers found that a paclitaxel combination improved median and long-term survival rates for patients with early-stage SCLC. The treatment also reduced side effects compared to standard chemotherapy.
A new treatment combining CPT-11 and cisplatin has shown superior results in prolonging survival for patients with small-cell lung cancer. Patients receiving this treatment had a 55% improvement in one-year survival and were four times more likely to be alive at two years.